Loading...
Market
What will be Organon's stock price at the end of 2024?
3
Resolution / Starting Odds
Less than $25 • 25%
$25 to $29.99 • 25%
$30 to $34.99 • 25%
$35 or more • 25%
Stock market data from financial news websites such as Bloomberg or Yahoo Finance
Story
Organon Acquires Roivant's Dermavant for $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 11:36 AM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences ($ROIV), in a deal valued at $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The deal involves an upfront payment of $175 million, with additional payments up to $1.2 billion contingent on sales milestones and approval in atopic dermatitis. This acquisition underscores Organon's commitment to expanding its portfolio in dermatology.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Strong Buy • 25%
Buy • 25%
Hold • 25%
Sell • 25%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Below $100 • 25%
$100-$150 • 25%
$150-$200 • 25%
Above $200 • 25%
Below $200 • 25%
$200 - $250 • 25%
$250 - $300 • 25%
Above $300 • 25%
Yes • 50%
No • 50%
Below €10 • 25%
€10 - €20 • 25%
€20 - €30 • 25%
Above €30 • 25%
Below 2,000 yen • 25%
2,000 - 3,000 yen • 25%
3,000 - 4,000 yen • 25%
Above 4,000 yen • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Less than $500 • 25%
$500 to $600 • 25%
$600 to $700 • 25%
More than $700 • 25%